Table 1 Clinicopathological data for HER2‑positive breast cancer patients
Parameters | Trastuzumab-sensitive cases (n = 12) | Trastuzumab-resistant cases (n = 12) | p |
|---|---|---|---|
Age (years) at initial diagnosis, | |||
 Min–max | 35.0–61.0 | 36.0–60.0 | 0.837 |
 Mean ± SD | 49.42 ± 9.35 | 50.17 ± 8.31 | |
Hormone receptor status at diagnosis | |||
 ER−, PR+, HER2+ | 1 (8.3%) | 0 (0%) | 0.521 |
 ER−, PR−, HER2+ | 6 (50%) | 8 (66.7%) | |
 ER+, PR−, HER2+ | 0 (0%) | 1 (8.3%) | |
 ER+, PR+, HER2+ | 5 (41.7%) | 3 (25%) | |
TNM stage | |||
 I | 2 (16.7%) | 0 (0%) | 0.365 |
 II | 6 (50%) | 5 (41.6%) | |
 III | 4 (33.3%) | 7 (58.4%) | |
Grade | |||
 Grade I | 0 (0%) | 0 (0%) | 1 |
 Grade II | 6 (50%) | 6 (50%) | |
 Grade III | 6 (50%) | 6 (50%) | |
Clinical course | |||
 Disease free | 12 (100%) | 0 (0%) |  |
 Local relapse | – | 5 (41.7%) | |
 Non-visceral metastasis (bone) | – | 4 (33.3%) | |
 Visceral metastasis (lung and brain) | – | 2 (16.7%) | |
 Death | – | 1 (8.3%) | |
Lines of therapy | |||
 Anti-HER2-targeted therapy |  |  |  |
  Trastuzumab (herceptin) | 12 (100%) | 12  (100%) | 1.000 |
 Chemotherapy: Doxorubicin (adriamycin)/cyclophosphamide, Paclitaxel (taxol), and/or Docetaxel (taxotere) | 12 (100%) | 12 (100%) | 1.000 |
 Hormonal therapy | 6 (50%) | 4 (33.3%) | 0.680 |